Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer

Clinical Cancer Research

Volumn 8, Issue 1, 2002, Pages 156-164

  Holten Andersen, Mads N ^a   Christensen, Ib Jarle ^a   Stephens, Ross W ^a   Jensen, Vibeke ^a   Brünner, Nils ^a   Nielsen, Hans Jørgen ^b   Nielsen, Ole Haagen ^c   Sørensen, Steen ^b   Overgaard, Jens ^d   Lilja, Hans ^e   Harris, Adrian ^f   Murphy, Gillian ^g  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD DONORS; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RECTAL NEOPLASMS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 0036156756     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Reducing mortality from colorectal cancer by screening for fecal occult blood
2. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
3. Randomised study of screening for colorectal cancer with faecal-occult-blood test
4. The association of preoperative serum tumour markers with Dukes’ stage and survival in colorectal cancer
5. Carcinoembryonic antigen (CEA) in colonic cancer. Use in preoperative and postoperative diagnosis and prognosis
6. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer
7. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection
8. Serum CEA testing in the postoperative surveillance of colorectal carcinoma
9. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9
10. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases
11. Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src
12. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells
13. Plasminogen activators, tissue degradation, and cancer
14. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: An immunohistochemical study
15. Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer
16. Identifying markers for pancreatic cancer by gene expression analysis
17. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients
18. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer
19. Human skin fibroblast collagenase: Interaction with substrate and inhibitor
20. Stability analysis of latent and active 72-kDa type IV collagenase: The role of tissue inhibitor of metalloproteinases-2 (TIMP-2)
21. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages
22. r progelatinase
23. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin
24. Matrix metalloproteinases: A review
25. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroidpotentiating activity
26. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family
27. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family
28. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
29. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP
30. Human skin fibroblast collagenase inhibitor. Comparative studies in human connective tissues, serum, and amniotic fluid
31. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum
32. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells
33. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1
34. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells
35. Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer
36. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer
37. Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients
38. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer
39. Plasma TIMP-1: A marker of metastasis in colorectal cancer
40. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer
41. High preoperative plasma tissue inhibitor of metalloproteinases-1 levels are associated with short survival of patients with colorectal cancer
42. Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962-87: A sixfold increase in incidence
43. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987
44. Serum antibodies to Bacteroides species in chronic inflammatory bowel disease
45. The classification of cancer of the rectum
46. Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum
47. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity
48. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes
49. The Cirrus IMMULITE: A new random access automated immunoassay system
50. The meaning and use of the area under a receiver operating characteristic (ROC) curve
51. Plasma assay of gelatinase B: Tissue inhibitor of metalloproteinase complexes in cancer
52. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers
53. Platelet-derived collagenase inhibitor: Characterization and subcellular localization
54. What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?
55. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumathoid arthritis
56. Increased levels of stromelysin-1 and tissue inhibitor of matrix metalloproteinases 1 in sera from patients with rheumatoid arthritis
57. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
58. Screening for colorectal cancer
59. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer
60. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: Relation to prognosis
61. Serum VEGF levels in patients with primary colorectal carcinoma
62. The urokinase plasminogen receptor in blood from healthy individuals and patients with cancer